Sector Expert: John Vandermosten

Zacks Small-Cap Research



Recent Quotes

"We view RVX's shares as undervalued, and in a position to provide long-term upside potential."

— John Vandermosten, Zacks Equity Research (6/14/17)
more >

"Our investment thesis for RVX is based on a large and growing underserved market in cardiovascular disease."

— John Vandermosten, Zacks Equity Research (3/30/17)
more >

— John Vandermosten, Zacks Equity Research (12/16/16)
more >

"RVX has identified six different pathways where apabetalone has shown promise in improving MACE."

— John Vandermosten, Zacks Equity Research (10/17/16)
more >

"RVX has increased the pace of investment into its portfolio of indications for apabetalone in recent quarters, launching a Phase 1 PK study with patients suffering from severe renal impairment and accelerating the pace of its BETonMACE study."

— John Vandermosten, Zacks Equity Research (9/22/16)
more >

"RVX's lead product candidate, apabetalone, is the first selective BET bromodomain inhibitor in clinical trials for high-risk vascular disease."

— John Vandermosten, Zacks Equity Research (7/29/16)
more >

"RVX shares as undervalued, and in a position to provide long-term upside potential."

— John Vandermosten, Zacks Small-Cap Research (6/29/16)
more >



Due to permission requirements, not all quotes are shown.